Apr. 2021 | Oncimmune announces the signature of Agreements with Roche and Cedars-Sinai to profile patients using Oncimmune’s novel Infectious Disease panel
Mar. 2021 | Pharnext Announces First Patient Enrolled in the PREMIER Trial, its Pivotal Phase III Clinical Development Program of PXT3003 in Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’)
